Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) shot up 6.6% on Tuesday after Canaccord Genuity Group raised their price target on the stock from $148.00 to $204.00. Canaccord Genuity Group currently has a buy rating on the stock. Palvella Therapeutics traded as high as $95.08 and last traded at $94.81. 136,382 shares were traded during mid-day trading, an increase of 3% from the average session volume of 131,872 shares. The stock had previously closed at $88.98.Get Palvella Therapeutics alerts:Other analysts have also issued research reports about the stock. BTIG Research lifted their target price on shares of Palvella Therapeutics from $167.00 to $192.00 and gave the stock a "buy" rating in a report on Monday. HC Wainwright set a $200.00 price objective on Palvella Therapeutics in a research note on Monday. Truist Financial upped their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the company a "buy" rating in a report on Monday. Oppenheimer restated an "outperform" rating and set a $200.00 target price on shares of Palvella Therapeutics in a report on Monday. Finally, Chardan Capital boosted their target price on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a "buy" rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $155.60.Check Out Our Latest Stock Analysis on PVLAInsider ActivityIn other news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total value of $370,961.46. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 20.50% of the stock is owned by company insiders. Institutional Investors Weigh In On Palvella TherapeuticsSeveral institutional investors and hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp bought a new position in shares of Palvella Therapeutics in the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. AlphaQuest LLC acquired a new position in shares of Palvella Therapeutics during the 3rd quarter worth approximately $164,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors. Palvella Therapeutics Stock PerformanceThe firm has a fifty day moving average price of $83.82 and a 200 day moving average price of $55.62. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -36.10 and a beta of -0.20. Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year. Palvella Therapeutics Company Profile (Get Free Report)Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa. Featured ArticlesFive stocks we like better than Palvella TherapeuticsHow to Invest in Insurance Companies: A Guide 3 AI Names With Big Buybacks: GEV, PSTG, and LSCC Signal ConfidenceWhat Investors Need to Know About Upcoming IPOsWestern Digital’s Nasdaq-100 Entry Caps Its AI-Driven Comeback3 REITs to Buy and Hold for the Long TermParamount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Palvella Therapeutics Right Now?Before you consider Palvella Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here